Zentalis Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	39.07	33.9	28.04	43.07	59.71	54.95
Short-Term Investments	241.63	337.18	454.88	394.3	280.17	283.55
Cash & Short-Term Investments	280.7	371.08	482.92	437.37	339.89	338.51
Cash Growth	-28.26%	-23.16%	10.41%	28.68%	0.41%	403.38%
Accounts Receivable	-	5	-	-	-	-
Other Receivables	-	-	-	-	-	0.42
Receivables	-	5	-	-	-	0.42
Prepaid Expenses	7.61	9.98	13.8	14.56	10.64	6.18
Restricted Cash	-	-	-	-	0.24	-
Total Current Assets	288.3	386.07	496.72	451.93	350.77	345.1
Property, Plant & Equipment	33.12	37.23	41.74	50.08	52.84	3.62
Long-Term Investments	-	-	-	21.21	37.5	-
Goodwill	-	-	3.74	3.74	3.74	3.74
Other Intangible Assets	-	-	-	-	-	8.8
Other Long-Term Assets	5.83	7.04	9.5	12.35	9.67	4.3
Total Assets	327.25	430.34	551.69	539.31	454.51	365.56
Accounts Payable	7.03	7.44	14.93	11.25	11.59	8.66
Accrued Expenses	25.89	42.22	51.54	42.85	29.93	18.63
Current Portion of Leases	3.75	3.07	2.62	2.16	1.45	0.9
Current Income Taxes Payable	-	-	0.28	0.38	0.97	0.41
Total Current Liabilities	37.17	52.73	69.37	56.65	43.94	28.6
Long-Term Leases	36.71	39.58	43.15	45.17	44.46	1.1
Long-Term Deferred Tax Liabilities	-	-	-	0.85	1.62	2.48
Other Long-Term Liabilities	0.5	0.85	1.78	2.62	-	-
Total Liabilities	74.38	93.15	114.3	105.29	90.03	32.18
Common Stock	0.07	0.07	0.07	0.06	0.05	0.04
Additional Paid-In Capital	1,409	1,391	1,324	1,031	723.59	509.34
Retained Earnings	-1,156	-1,054	-888.56	-596.37	-359.56	-200.83
Comprehensive Income & Other	0.19	0.56	2.19	-1.35	-0.13	0.04
Total Common Equity	252.87	337.19	437.28	433.8	363.95	308.58
Minority Interest	-	-	0.11	0.22	0.53	24.8
Shareholders' Equity	252.87	337.19	437.39	434.02	364.48	333.38
Total Liabilities & Equity	327.25	430.34	551.69	539.31	454.51	365.56
Total Debt	40.46	42.65	45.77	47.33	45.91	2
Net Cash (Debt)	240.24	328.44	437.15	390.04	293.98	336.51
Net Cash Growth	-30.96%	-24.87%	12.08%	32.68%	-12.64%	406.29%
Net Cash Per Share	3.35	4.62	6.68	7.38	6.89	11.97
Filing Date Shares Outstanding	72.25	71.81	70.96	59.42	45.56	41.04
Total Common Shares Outstanding	72.25	71.28	70.77	59.28	45.49	41.04
Working Capital	251.13	333.34	427.35	395.29	306.83	316.5
Book Value Per Share	3.50	4.73	6.18	7.32	8.00	7.52
Tangible Book Value	252.87	337.19	433.55	430.07	360.22	296.05
Tangible Book Value Per Share	3.50	4.73	6.13	7.25	7.92	7.21
Machinery	1.42	4.81	4.56	4.84	4.39	0.95
Construction In Progress	-	-	0.17	0.04	0.03	0.35
Leasehold Improvements	4.17	4.17	4.24	4.89	4.52	0.05

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q